Home > Dermatology > Adjuvant pembrolizumab may cut recurrence, mortality in stage-II melanoma

Adjuvant pembrolizumab may cut recurrence, mortality in stage-II melanoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The Lancet
Reuters Health - 14/04/2022 - Pembrolizumab as adjuvant therapy for patients with resected, high-risk stage-IIB or -IIC melanoma appears to reduce the risk of disease recurrence or death, according to interim analyses from the KEYNOTE-716 trial. "These data indicate that adjuvant therapy with pembrolizumab might become a treatment option for patients with resected stage IIB or IIC melanoma, but overall survival data are awaited," Dr. Jason J. Luke of the Hillman Cancer Center, University of Pittsburgh Medical Center, and colleagues conclude in The Lancet. To the researchers' knowledge, theirs is the first phase-3 trial to show a significant reduction in the risk of recurrence or death with anti-PD-1 or anti-PD-L1 therapy in patients with completely resected, high-risk stage-II melanoma. Recruited through 160 centers in 16 nations, patients were ages 12 and older with newly diagnosed, completely resected, histologically confirmed stage-IIB or -IIC cutaneous me...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on